within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AX12_Aripiprazole;

model Aripiprazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.87,
    Cl = 1.3611111111111111e-05,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.004900000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00038333333333333334,
    Tlag = 600,
    Vdp = 0.0027,
    k12 = 2.625e-06,
    k21 = 2.625e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aripiprazole</td></tr><tr><td>ATC code:</td><td>N05AX12</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>4.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.7</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aripiprazole is an atypical antipsychotic medication mainly used in the treatment of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at 5-HT2A receptors. Aripiprazole is approved and widely used today in many countries.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Wang, Y, et al., &amp; Raoufinia, A (2024). Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. <i>Clinical pharmacology in drug development</i> 13(6) 631–643. DOI:<a href=\"https://doi.org/10.1002/cpdd.1397\">10.1002/cpdd.1397</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38602057/\">https://pubmed.ncbi.nlm.nih.gov/38602057</a></p></li><li><p>Wang, X, et al., &amp; Phillips, L (2022). Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia. <i>Clinical pharmacology in drug development</i> 11(2) 150–164. DOI:<a href=\"https://doi.org/10.1002/cpdd.1022\">10.1002/cpdd.1022</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34979059/\">https://pubmed.ncbi.nlm.nih.gov/34979059</a></p></li><li><p>Kubo, M, et al., &amp; Azuma, J (2007). Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. <i>Drug metabolism and pharmacokinetics</i> 22(5) 358–366. DOI:<a href=\"https://doi.org/10.2133/dmpk.22.358\">10.2133/dmpk.22.358</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17965519/\">https://pubmed.ncbi.nlm.nih.gov/17965519</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AX12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aripiprazole;
